myTomorrows
 | This article needs additional citations for verification. (January 2019) |
CSO) | |
| Products | Experimental drugs |
|---|---|
| Website | mytomorrows.com |
myTomorrows is the trade name of Impatients N.V., a globally active
clinical trials, expanded access and off-label use
.
myTomorrows was founded in 2012 by Ronald Brus, former CEO of the
Chief Scientific Officer.[6]
References
- ^ a b "Dutch life science startup offers access to late-stage drugs for patients with few options". MedCity News. 2014-02-20. Retrieved 20 November 2018.
- ^ "MyTomorrows, dernière chance pour des patients". Le Monde. Retrieved 21 November 2018.
- ^ "myTomorrows raises further 10M to help access drugs in development". TechCrunch. Retrieved 20 November 2018.
- ^ "Patients' Right To Try Should Not Be A License To Fleece Them". Forbes. Retrieved 8 January 2019.
- ^ a b "myTomorrows is de Uber van de medicijnen". NRC Handelsblad. Retrieved 21 November 2018.
- ^ "Plasterk gaat naar farmabedrijf Mytomorrows". NU.nl. Retrieved 21 November 2018.
External links
 | This Dutch corporation or company article is a stub. You can help Wikipedia by expanding it. |